Intratumoral inflammation is associated with more aggressive prostate cancer

World Journal of Urology

Volumn 31, Issue 6, 2013, Pages 1497-1503

  Klink, Joseph C ^a,b,c   Bañez, Lionel L ^a,b   Gerber, Leah ^b   Lark, Amy ^a   Vollmer, Robin T ^a   Freedland, Stephen J ^a,b  

^a DURHAM VA MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Adverse pathology; Biochemical progression; Inflammation; Prostate cancer; Radical prostatectomy

Indexed keywords

ADENOCARCINOMA; AGED; ARTICLE; BIOPSY; DISEASE COURSE; HUMAN; INFLAMMATION; MALE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROSTATE; PROSTATE TUMOR; PROSTATECTOMY; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX;

ADENOCARCINOMA; AGED; BIOPSY; DISEASE PROGRESSION; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PROGNOSIS; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84888229434     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-013-1065-8     Document Type: Article

References (19)

1. Dennis LK, Lynch CF, Torner JC (2002) Epidemiologic association between prostatitis and prostate cancer. Urology 60(1): 78-83.
2. Nelson WG, De Marzo AM, DeWeese TL, Isaacs WB (2004) The role of inflammation in the pathogenesis of prostate cancer. J Urol 172(5 Pt 2): S6-S11 discussion S11-12.
3. Haverkamp J, Charbonneau B, Ratliff TL (2008) Prostate inflammation and its potential impact on prostate cancer: a current review. J Cell Biochem 103(5): 1344-1353.
4. Mahmud SM, Franco EL, Aprikian AG (2010) Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: a meta-analysis. Int J Cancer 127(7): 1680-1691.
5. Jafari S, Etminan M, Afshar K (2009) Nonsteroidal anti-inflammatory drugs and prostate cancer: a systematic review of the literature and meta-analysis. Can Urol Assoc J 3(4): 323-330.
6. Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE (2007) A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 99(8): 608-615.
7. Mahmud SM, Tanguay S, Begin LR, Franco EL, Aprikian AG (2006) Non-steroidal anti-inflammatory drug use and prostate cancer in a high-risk population. Eur J Cancer Prev 15(2): 158-164.
8. Habel LA, Zhao W, Stanford JL (2002) Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the US. Cancer Causes Control 13(5): 427-434.
9. Leitzmann MF, Stampfer MJ, Ma J et al (2002) Aspirin use in relation to risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 11(10 Pt 1): 1108-1111.
10. Schreinemachers DM, Everson RB (1994) Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5(2): 138-146.
11. Sun J, Turner A, Xu J, Gronberg H, Isaacs W (2007) Genetic variability in inflammation pathways and prostate cancer risk. Urol Oncol 25(3): 250-259.
12. Davidsson S, Fiorentino M, Andren O et al (2011) Inflammation, focal atrophic lesions, and prostatic intraepithelial neoplasia with respect to risk of lethal prostate cancer. Cancer Epidemiol Biomarkers Prev 20(10): 2280-2287.
13. Zhang W, Sesterhenn IA, Connelly RR, Mostofi FK, Moul JW (2000) Inflammatory infiltrate (prostatitis) in whole mounted radical prostatectomy specimens from black and white patients is not an etiology for racial difference in prostate specific antigen. J Urol 163(1): 131-136.
14. Irani J, Levillain P, Goujon JM, Bon D, Dore B, Aubert J (1997) Inflammation in benign prostatic hyperplasia: correlation with prostate specific antigen value. J Urol 157(4): 1301-1303.
15. Irani J, Goujon JM, Ragni E et al (1999) High-grade inflammation in prostate cancer as a prognostic factor for biochemical recurrence after radical prostatectomy. Pathologist multi center study group. Urology 54(3): 467-472.
16. McArdle PA, Canna K, McMillan DC, McNicol AM, Campbell R, Underwood MA (2004) The relationship between T-lymphocyte subset infiltration and survival in patients with prostate cancer. Br J Cancer 91(3): 541-543.
17. Nonomura N, Takayama H, Nakayama M et al (2011) Infiltration of tumour-associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer. BJU Int 107(12): 1918-1922.
18. Higano CS, Schellhammer PF, Small EJ et al (2009) Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115(16): 3670-3679.
19. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Partin AW (2006) Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality. J Urol 176(4 Pt 1): 1404-1408.